Ce protocole s'applique aux adultes présentant un astrocytome anaplasique, grade OMS 3 du SNC, chez qui les tests moléculaires confirment l'absence de mutation IDH (IDH-sauvage). Cette découverte moléculaire est un déterminant clé de l'approche thérapeutique pour cette population.
Les détails complets du protocole — tous les composants, le séquençage, les critères d'éligibilité — sont disponibles via le régime structuré ci-dessous.
DOI: 10.1093/neuonc/noab279
People with astrocytomas, IDH-wildtype, CNS WHO grade 2 or 3 may be treated according to recommendations for glioblastoma, IDH-wildtype, CNS WHO grade 4 found in this guideline (Type: informal consensus; Evidence quality: very low; Strength of recommendation: weak).
Concurrent TMZ and RT should be offered to people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).
Six months of adjuvant TMZ should be offered to people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 who have received concurrent RT plus TMZ (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).
Alternating electric field therapy may be added to adjuvant TMZ in people with newly diagnosed supratentorial glioblastoma, IDH-wildtype, CNS WHO grade 4 who have completed chemoradiation therapy (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: weak).
View source ↗